Pharsh Pharma provides a broad range of clinical research services, for studies into the world’s most prevalent airway diseases, including asthma and chronic obstructive pulmonary disease (COPD).
In Nigeria and Sub-Saharan Africa, asthma and COPD are particularly relevant as risk factors such as smoking, pollution, and tuberculosis (TB) are higher than in other regions. Most asthma related deaths still occur in low-to-mid income countries. COPD is currently the fourth leading cause of death, expected to become the third by 2030.
Our services in respiratory health include: